Preventing ASCVD Events: Using Coronary Artery Calcification Scores to Personalize Risk and Guide Statin Therapy

Area of Science:

• Cardiology
• Pulmonology
• Radiology

Background:

• Lung cancer is a leading cause of cancer mortality, with smoking as the primary risk factor.
• Smokers at high risk for lung cancer also face significant risks of atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality.
• Lung cancer screening (LCS) presents an opportunity for ASCVD event prevention.

Purpose of the Study:

• To review the clinical differences in using coronary artery calcification (CAC) scores for primary prevention and statin therapy guidance in smokers undergoing LCS.
• To provide recommendations for integrating CAC scores into ASCVD risk management within the LCS setting.

Main Methods:

• Review of existing literature on CAC scoring from low-dose computed tomography (LDCT) in LCS.
• Analysis of differences in CAC score interpretation for smokers versus the general population.
• Synthesis of recommendations for ASCVD prevention strategies during LCS.

Main Results:

• LDCT scans used for LCS can reveal the extent of CAC, an independent ASCVD risk factor.
• CAC scoring interpretation and its application in guiding primary prevention and statin therapy differ for LCS-eligible smokers compared to the general population.
• Integrating CAC findings into LCS protocols can enhance ASCVD risk stratification.

Conclusions:

• CAC scores derived from LDCT during LCS can inform ASCVD event prevention strategies.
• Recommendations are provided for utilizing CAC scores, incorporating cardiac testing, and determining the need for cardiovascular specialist referral in LCS patients.
• Optimizing ASCVD risk management within LCS programs is crucial for high-risk smokers.